Healthcare

Taysha Gene Therapies is building gene therapies for severe neurological disorders, with TSHA-102 in Rett syndrome as the central value driver. The company stands out for its focused pipeline and improving balance-sheet position, even though its future still depends on clinical execution.

Stoke Therapeutics is building RNA medicines for rare genetic diseases, led by zorevunersen in Dravet syndrome. Its platform approach and Biogen-backed partnership make it a closely watched name where future value depends on clinical progress and execution.

Syndax is a small oncology biotech that has moved into commercialization with Revuforj, giving it real revenue alongside a targeted leukemia pipeline. The appeal centers on franchise expansion potential in blood cancers and a second asset that could broaden its platform.

Sarepta Therapeutics is a rare-disease biotech centered on Duchenne muscular dystrophy, combining approved exon-skipping drugs with gene therapy. Its revenue base became substantial, and the key question now is whether Elevidys can turn scientific progress into durable execution.

Sihuan Pharmaceutical is reshaping itself from a legacy branded-generic drug maker into a broader healthcare group spanning specialty pharma and medical aesthetics. A 2025 recovery in revenue and operating profit makes the transition worth a closer look.